We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
BSX Q3 Earnings Call Flags Growth Challenges Through 2027
Read MoreHide Full Article
Key Takeaways
BSX expects revenue and earnings growth to remain challenged in 2027, with recovery beginning in 2028.
A cybersecurity incident cost BSX roughly $150 million in Q3 sales and 7 cents in adjusted EPS.
BSX faces EP, WATCHMAN competition and China pricing pressure while targeting over $500 million in savings.
Boston Scientific Corporation (BSX - Free Report) outlined a challenging near-term outlook during its third-quarter 2026 earnings call, citing mounting competitive pressures, cybersecurity disruptions and unfavorable pricing dynamics in China.
Management expects 2027 to mark the trough of its current business cycle, with revenue and adjusted earnings growth remaining under pressure before a recovery driven by product innovation and restructuring initiatives in 2028.
BSX Faces a Difficult Growth Outlook for 2027
Chairman and CEO Michael Mahoney acknowledged that the company's Electrophysiology (“EP”) and WATCHMAN franchises have transitioned from major growth contributors into significant headwinds.
Management expects fourth-quarter organic revenues to decline 1%-3%, with adjusted earnings of 77-79 cents per share. Full-year organic revenue growth is projected at approximately 3.75%, with adjusted earnings of $3.16-$3.18 per share.
Mahoney expects revenue and adjusted earnings growth to remain challenged in 2027, excluding the pending Penumbra acquisition. The company anticipates improved performance in 2028, followed by further acceleration in 2029.
Boston Scientific Details Cybersecurity Disruption
Chief financial officer Jonathan Monson attributed approximately 300 basis points of third-quarter revenue growth pressure to the cybersecurity incident, equivalent to roughly $150 million in lost sales.
The disruption reduced adjusted earnings by approximately 7 cents per share. Despite restoring operations by Sept. 8, management anticipates another 200-300 basis points of revenue pressure in the fourth quarter as customers normalize inventory levels.
Adjusted earnings totaled 73 cents per share, in line with the Zacks Consensus Estimate. Third-quarter revenues reached $5.14 billion, which beat the consensus mark of $5.10 billion.
Boston Scientific Corporation Price, Consensus and EPS Surprise
BSX Confronts EP and WATCHMAN Competitive Pressures
Mahoney reported that EP revenues declined 5%, including an 8% contraction in the United States. Competitive product introductions continue to erode the company's pulsed-field ablation market share.
The WATCHMAN franchise declined 6%, reflecting weaker standalone procedures and changing physician referral patterns. Management expects continued competitive pressure in 2027 despite investments in physician education and commercial resources.
During the JPMorgan Q&A, Mahoney clarified that the company's 2027 outlook assumes no meaningful WATCHMAN market recovery. EP improvement depends heavily on the planned FARAWAVE Ultra launch in early 2028 and FARAFLEX introduction in 2029.
Boston Scientific Advances Restructuring and Innovation
Monson expects the restructuring program to generate more than $500 million in savings over three years, with more than half achieved by the end of 2027.
The initiative targets organizational simplification, supply-chain optimization, shared services and discretionary spending. Management intends to preserve investments in strategically important product platforms despite near-term margin pressures.
Responding to BTIG's questions, Monson identified product mix as the primary obstacle to 2027 earnings growth. Weakness in EP and WATCHMAN, combined with Chinese pricing pressure, is expected to constrain gross margins.
BSX Targets Portfolio Expansion Despite Delays
Interventional Cardiology delivered 19% growth, supported by imaging technologies and drug-eluting products. Neuromodulation increased 13%, providing another source of underlying strength.
Management expects the Penumbra acquisition to close in early 2027, subject to regulatory approvals. During the Jefferies Q&A, Monson cautioned that higher financing costs could increase the transaction's previously anticipated earnings dilution.
The pipeline also faces execution challenges. During Piper Sandler's questioning, Cardiovascular Group president Joseph Fitzgerald attributed FARAWAVE Ultra delays to design verification and validation, while FARAFLEX faces clinical enrollment and operational hurdles.
Boston Scientific Focuses on Rebuilding Execution
Mahoney emphasized organizational accountability, forecasting improvements and disciplined investment as central priorities for restoring performance.
Monson acknowledged previous forecasting shortcomings and outlined enhanced scenario analysis, objective modeling and third-party data integration. Management remains focused on stabilizing operations in 2027 while positioning the business for stronger growth thereafter.
What BSX's Zacks Rank and Style Scores Indicate
BSX currently carries a Zacks Rank #4 (Sell), reflecting an unfavorable near-term earnings estimate revision outlook. Its Value and Growth Scores of B indicate relatively favorable characteristics in those categories, while its Momentum Score of D signals weaker momentum. The stock also carries a VGM Score of B.
Although the favorable Value, Growth and VGM Scores highlight certain underlying attributes, the Zacks Rank #4 warrants caution under the combined ranking framework. The Zacks Rank can change as analysts revise earnings estimates following the latest quarterly results.
View the Zacks #1 Rank List
Image: Bigstock
BSX Q3 Earnings Call Flags Growth Challenges Through 2027
Key Takeaways
Boston Scientific Corporation (BSX - Free Report) outlined a challenging near-term outlook during its third-quarter 2026 earnings call, citing mounting competitive pressures, cybersecurity disruptions and unfavorable pricing dynamics in China.
Management expects 2027 to mark the trough of its current business cycle, with revenue and adjusted earnings growth remaining under pressure before a recovery driven by product innovation and restructuring initiatives in 2028.
BSX Faces a Difficult Growth Outlook for 2027
Chairman and CEO Michael Mahoney acknowledged that the company's Electrophysiology (“EP”) and WATCHMAN franchises have transitioned from major growth contributors into significant headwinds.
Management expects fourth-quarter organic revenues to decline 1%-3%, with adjusted earnings of 77-79 cents per share. Full-year organic revenue growth is projected at approximately 3.75%, with adjusted earnings of $3.16-$3.18 per share.
Mahoney expects revenue and adjusted earnings growth to remain challenged in 2027, excluding the pending Penumbra acquisition. The company anticipates improved performance in 2028, followed by further acceleration in 2029.
Boston Scientific Details Cybersecurity Disruption
Chief financial officer Jonathan Monson attributed approximately 300 basis points of third-quarter revenue growth pressure to the cybersecurity incident, equivalent to roughly $150 million in lost sales.
The disruption reduced adjusted earnings by approximately 7 cents per share. Despite restoring operations by Sept. 8, management anticipates another 200-300 basis points of revenue pressure in the fourth quarter as customers normalize inventory levels.
Adjusted earnings totaled 73 cents per share, in line with the Zacks Consensus Estimate. Third-quarter revenues reached $5.14 billion, which beat the consensus mark of $5.10 billion.
Boston Scientific Corporation Price, Consensus and EPS Surprise
Boston Scientific Corporation price-consensus-eps-surprise-chart | Boston Scientific Corporation Quote
BSX Confronts EP and WATCHMAN Competitive Pressures
Mahoney reported that EP revenues declined 5%, including an 8% contraction in the United States. Competitive product introductions continue to erode the company's pulsed-field ablation market share.
The WATCHMAN franchise declined 6%, reflecting weaker standalone procedures and changing physician referral patterns. Management expects continued competitive pressure in 2027 despite investments in physician education and commercial resources.
During the JPMorgan Q&A, Mahoney clarified that the company's 2027 outlook assumes no meaningful WATCHMAN market recovery. EP improvement depends heavily on the planned FARAWAVE Ultra launch in early 2028 and FARAFLEX introduction in 2029.
Boston Scientific Advances Restructuring and Innovation
Monson expects the restructuring program to generate more than $500 million in savings over three years, with more than half achieved by the end of 2027.
The initiative targets organizational simplification, supply-chain optimization, shared services and discretionary spending. Management intends to preserve investments in strategically important product platforms despite near-term margin pressures.
Responding to BTIG's questions, Monson identified product mix as the primary obstacle to 2027 earnings growth. Weakness in EP and WATCHMAN, combined with Chinese pricing pressure, is expected to constrain gross margins.
BSX Targets Portfolio Expansion Despite Delays
Interventional Cardiology delivered 19% growth, supported by imaging technologies and drug-eluting products. Neuromodulation increased 13%, providing another source of underlying strength.
Management expects the Penumbra acquisition to close in early 2027, subject to regulatory approvals. During the Jefferies Q&A, Monson cautioned that higher financing costs could increase the transaction's previously anticipated earnings dilution.
The pipeline also faces execution challenges. During Piper Sandler's questioning, Cardiovascular Group president Joseph Fitzgerald attributed FARAWAVE Ultra delays to design verification and validation, while FARAFLEX faces clinical enrollment and operational hurdles.
Boston Scientific Focuses on Rebuilding Execution
Mahoney emphasized organizational accountability, forecasting improvements and disciplined investment as central priorities for restoring performance.
Monson acknowledged previous forecasting shortcomings and outlined enhanced scenario analysis, objective modeling and third-party data integration. Management remains focused on stabilizing operations in 2027 while positioning the business for stronger growth thereafter.
What BSX's Zacks Rank and Style Scores Indicate
BSX currently carries a Zacks Rank #4 (Sell), reflecting an unfavorable near-term earnings estimate revision outlook. Its Value and Growth Scores of B indicate relatively favorable characteristics in those categories, while its Momentum Score of D signals weaker momentum. The stock also carries a VGM Score of B.
Although the favorable Value, Growth and VGM Scores highlight certain underlying attributes, the Zacks Rank #4 warrants caution under the combined ranking framework. The Zacks Rank can change as analysts revise earnings estimates following the latest quarterly results.
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.